Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKinsey
Moodys
Cipla
US Army
Federal Trade Commission
Healthtrust
Deloitte
Merck

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206510

« Back to Dashboard

NDA 206510 describes DUTREBIS, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are five patents protecting this drug. Additional details are available on the DUTREBIS profile page.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-eight drug master file entries for this compound. Additional details are available on the lamivudine; raltegravir potassium profile page.
Summary for 206510
Tradename:DUTREBIS
Applicant:Merck Sharp Dohme
Ingredient:lamivudine; raltegravir potassium
Patents:5
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength150MG;EQ 300MG BASE
Approval Date:Feb 6, 2015TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Apr 3, 2024Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Apr 21, 2023Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Apr 21, 2023Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
McKinsey
US Department of Justice
QuintilesIMS
Argus Health
US Army
Dow
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.